Posted by Michael Wonder on 11 Apr 2022
UK patients granted early access for radioligand therapy in advanced prostate cancer
8 April 2022 - Advanced Accelerator Applications has announced that eligible patients in the UK have been granted early access for radioligand therapy in advanced prostate cancer, a disease which causes over 11,500 deaths in the UK alone each year.
A positive scientific opinion has been issued for lutetium (Lu 177) vipivotide tetraxetan, for the Early Access to Medicines Scheme by the MHRA for use in eligible patients with advanced prostate cancer.
